PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2009 | 4 | 1 | 98-103
Tytuł artykułu

Teat tablet with sodium ibuprofen: the effect of sorbitol on therapeutic agent pharmaceutical availability and on physicochemical parameters of a drug form

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Dosing pediatric drugs available on pharmaceutical markets of analgesic, antifebrile and anti-inflammatory activity to children up to 3 years of age is not precise and frequently causes problems. The aim of the study was to work out a pediatric teat form of a drug with sodium ibuprofen and to determine the effect of sorbitol content on pharmaceutical availability of the therapeutic agent. Three variants of tablets containing 50 mg of sodium ibuprofen differing in the percentage content of sorbitol (from 37% - batch I to 79% - batch III) were produced. Quality tests of the produced forms of drugs (PPVI) were performed and the tests of therapeutic agent pharmaceutical availability by spatula method and by a method with a teat. Tablets of all batches had a smooth surface and same shape. The content of the therapeutic agent was within the limit of 95-105% of the declared value. The highest value of Q coefficient in the release test by pharmacopeal method and the shortest disintegration time (12 minutes) were obtained for tablets with 79% content of sorbitol. In conclusion, teat tablets with sodium ibuprofen of the highest sorbitol content (79%) demonstrated the expected physicochemical parameters and high pharmaceutical availability.
Słowa kluczowe
Wydawca
Czasopismo
Rocznik
Tom
4
Numer
1
Strony
98-103
Opis fizyczny
Daty
wydano
2009-03-01
online
2009-02-11
Twórcy
  • Department of Applied Pharmacy, Medical University of Lodz, 90-151, Lodz, Poland
  • Department of Applied Pharmacy, Medical University of Lodz, 90-151, Lodz, Poland
  • Department of Anaesthesiology and Intensive Care Unit, Boleslaw Szarecki University Hospital No. 5 in Lodz, Medical University of Lodz, 90-647, Lodz, Poland
autor
  • Department of Applied Pharmacy, Medical University of Lodz, 90-151, Lodz, Poland
Bibliografia
  • [1] Lesko S.M., Mitchell A.A., Renal function after shortterm ibuprofen use in infants and children, Pediatrics, 1997, 100, 954–957 http://dx.doi.org/10.1542/peds.100.6.954[Crossref]
  • [2] Radzikowski A., Gastrotoksyczność niesteroidowych leków przeciwzapalnych, Pediatria Współczesna, Gastroenterologia, Hepatologia Żywienie Dziecka, 1999, 1, 41–43 (Polish)
  • [3] Lesko S.M., Mithell A.A., The safety of acetaminofen and ibuprofen among children younger than two years old, Pediatrics, 1999, 104, 39 http://dx.doi.org/10.1542/peds.104.4.e39[Crossref]
  • [4] Litalien C., Jacqz-Aigrain E., Risks and benefits of nonsteroidal anti - inflammatory drugs in children: a comprasion with paracetamol, Pediatr. Drugs, 2001, 3, 817–858 http://dx.doi.org/10.2165/00128072-200103110-00004[Crossref]
  • [5] Lesko S.M., The safety of ibuprofen suspension in children, Int. J. Pract. Suppl., 2003, 135, 50–53
  • [6] Purssell E., Treating fever in children: paracetamol or ibuprofen? Br. J. Community Nurs., 2002, 7, 316–20 [PubMed]
  • [7] Goldman R.D., Ko K., Linett L.J., Scolnik D., Antipyretic efficacy and safety of ibuprofen and acetaminophen in children, Ann. Pharmacother., 2004, 38, 146–50 http://dx.doi.org/10.1345/aph.1C391[Crossref]
  • [8] Radzikowski A., Albrecht P., Burdan F., Czywystarczy paracetamol? Ibuprofen lek bezpieczny i skuteczny, Pediatria po Dyplomie 2000, 7 (wyd. specjalne), 11–19 (Polish)
  • [9] Lesko S.M., Louik C., Vezina R.M., Mitchel A.A., Asthma morbidity after short-term use of ibuprofen in children, Pediatrics, 2002, 109, 20 http://dx.doi.org/10.1542/peds.109.2.e20[Crossref]
  • [10] Simon R.E., Ibuprofen suspension: pediatric antipyretic, Pediatr. Nurs., 1996, 22, 118–20
  • [11] Aranda J.V., Varvarigou A., Beharry K., Bansal R., Bardin C., Modanlon H., et al., Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant, Acta Pediatr., 1997, 86, 289–293 http://dx.doi.org/10.1111/j.1651-2227.1997.tb08892.x[Crossref]
  • [12] Kornacka K.M., Kłosińska I., Bober K., Ibuprofen w leczeniu przetrwałego przewodu tętniczego u noworodków, Ordynator Leków, 2002, 11–12, 35–36 (Polish)
  • [13] Supapannachart S., Limrungsikul A., Khowsathit P., Oral ibuprofen and indomethacin for treatment of patent duetus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital, J. Med. Assoc. Thai., 2002, 85(Suppl. 4), 1252–1258
  • [14] Autret-Leca E., Gibb I.A., Goulder M.A., Ibuprofen versus paracetamol in pediatric fever: objective and subjective findings from a randomized, blinded study, Curr. Med. Res. Opin., 2007, 23, 2205–11 http://dx.doi.org/10.1185/030079907X223323[WoS][Crossref]
  • [15] Kermond S., Fink M., Graham K., Carlin J.B., Barnett P., Stosowanie ibuprofenu u dzieci z przejściowym zapaleniem stawu biodrowego skracało czas utrzymywania się objawów choroby, Medycyna Praktyczna - Pediatria, 2003, 1, 127–129 (Polish)
  • [16] Lewis D.W., Kellstein D., Dahl G., Burke B., Frank L.M., Toor S., et al., Children’s ibuprofen suspension for the acute treatment of pediatric migraine, Headache, 2002, 42, 780–6 http://dx.doi.org/10.1046/j.1526-4610.2002.02180.x[Crossref]
  • [17] Bidel S., Hu G., Tuomilehto J., Coffee consumption and type 2 diabetes - An extensive review, Cent. Eur. J. Med., 2008, 3, 9–19 http://dx.doi.org/10.2478/s11536-007-0059-6[WoS][Crossref]
  • [18] Dooley J.M., Gordon K.E., Wood E.P., Brna P.M., Macsween J., Fraser A., Caffeine as an adjuvant to Ibuprofen in treating childhood headaches, Pediatr. Neurol., 2007, 37, 42–46 http://dx.doi.org/10.1016/j.pediatrneurol.2007.02.016[WoS][Crossref]
  • [19] St Charles C.S., Matt B.H., Hamilton M.M., Katz B.P., A comparison of ibuprofen versus acetaminophen with codeine in the young tonsillectomy patient, Otolaryngol. Head Neck. Surg., 1997, 117, 76–82 http://dx.doi.org/10.1016/S0194-5998(97)70211-0[Crossref]
  • [20] Díez Domingo J., Planelles Cantarino M.V., Moreno Madrid F., Uberos Fernández J., Moreno Martín J., Molina Carballo A., et al. Evaluation of the antipyretic safety and accuracy of two pediatric ibuprofen formulations, Ann. Esp. Pediatr., 2000, 53, 436–40
  • [21] Kokki H., Kumpulainen E., Lehtonen M., Laisalmi M., Heikkinen M., Sayolainen J., et al., Cerebrospinal fluid distribution of ibuprofen after intravenous administration in children, Pediatrics, 2007, 120, 1002–8 http://dx.doi.org/10.1542/peds.2007-0064[Crossref][WoS]
  • [22] Sagraves R., Pediatric dosing and dosage forms. In: Dekker M, editor. Encyklopedia of Pharmaceutical Technology, 2000, pp. 2045–2065
  • [23] Berner A., Zgoda M.M., Formulacja i badanie dostępności farmaceutycznej jonu fluorkowego z tabletek dosmoczkowych, Biuletyn Kosmetol., 1998, 3, 125–131 (Polish)
  • [24] Mentes A., pH changes in dental plaque after using sugar-free pediatric medicine, J. Clin. Pediatr. Dent., 2001, 25, 307–12 [Crossref][PubMed]
  • [25] Limanowska-Shaw H., Praktyczne aspekty zapobiegania próchnicy zębów, Terapia, 2003, 5, 43–45 (Polish)
  • [26] Brikhed D., Svensater G., Edwardsson S., Cariological studies of idividuals with long - term sorbitol consumption, Caries Res., 1990, 24, 220–223 http://dx.doi.org/10.1159/000261269[Crossref]
  • [27] Svanberg M., Birkhed D., Effect of Dentifrices containing either Xylitol and Glycerol or Sorbitol on Mutans Streptococci in Saliva. Caries Res., 1991, 25, 449–453 [PubMed][Crossref]
  • [28] Farmakopea PolskaVII, Tom I, Polskie Towarzystwo Farmaceutyczne, Warszawa 2006 (Polish)
  • [29] European Pharmacopeia 5th Edition, Volume I. Council of Europe, Strasbourg 2006 (Polish)
  • [30] Banach M., Rysz J., Goch A., Mikhailidis D.P., Rosano G.M., The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol. 2008, 6, 282–91 http://dx.doi.org/10.2174/157016108785909788[Crossref]
  • [31] Samczewska G., Kołodziejska J., Ciałkowska-Rysz A., Piechota-Urbañska M., The effect of cross-linking base on the properties of hydrogels with Carbopol and on pharmaceutical availability of morphine sulphate, Arch. Med. Sci., 2007, 3, 19–26
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-008-0087-x
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.